Pfizer is to fund research into the application of stem cells in degenerative retinal disease through a $3 million investment in EyeCyte, a company based in California, US.
Pfizer is to fund research into the application of stem cells in degenerative retinal disease through a $3 million investment in EyeCyte, a company based in California, US.
EyeCyte, a spin-off of the laboratory of Professor Martin Friedlander, MD, PhD at the Scripps Research Institute, is currently investigating the role of stem and progenitor cells in the treatment of diabetic retinopathy. Other acquired and inherited retinal diseases the company is investigating include age-related macular degeneration, retinopathy of prematurity, retinal vascular occlusive disease and retinitis pigmentosa.
Professor Friedlander's research, funded by grants from the National Eye Institute (NEI) and the National Institutes of Health (NIH), has demonstrated that stem cells and progenitor cells can target neovascularization and halt the degeneration of the vasculature in animal models.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.